{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:52:00Z","timestamp":1791370320911,"version":"4.3.1"},"reference-count":182,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematological malignancies, yet its efficacy in solid tumors remains limited by inefficient trafficking, suppressive myeloid and regulatory T-cell populations, and metabolic stress. These barriers contribute to incomplete tumor cell killing and loss of CAR-T cell function. Chemokines are usually viewed as migratory guides, but in solid tumors they also orchestrate immune cell positioning and inflammatory state. In this review, we discuss how chemokine gradients form inflammatory niches and control CAR-T-cell recruitment, intratumoral distribution, retention, and egress. We also examine how chemokine programs interact with cytokine signaling and regulated tumor cell death to shape local and potentially tissue-wide antitumor immunity, including through the release of damage-associated molecular patterns (DAMPs). Finally, we outline translational strategies that include engineered chemokines and matched chemokine receptor programs to enhance the efficacy of chemokine\/cytokine-armored CAR-T cells, and related combination therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1963794","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:12:09Z","timestamp":1791367929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemokines as regulators of CAR-T cell trafficking, function, and context-dependent tumor cell death"],"prefix":"10.3389","volume":"17","author":[{"given":"Ksenia","family":"Levchuk","sequence":"first","affiliation":[{"name":"Institute of Cytology, Russian Academy of Sciences","place":["St. Petersburg, Russia"]},{"name":"Laboratory of Molecular Oncology, National Laboratory Astana","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Petukhov","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, National Laboratory Astana","place":["Astana, Kazakhstan"]},{"name":"Department of Biomedical Sciences, School of Medicine, Nazarbayev University","place":["Astana, Kazakhstan"]},{"name":"Limited Liability Partnership (LLP) Center of Hematology","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shynggys","family":"Tursymbek","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, National Laboratory Astana","place":["Astana, Kazakhstan"]},{"name":"Department of Biomedical Sciences, School of Medicine, Nazarbayev University","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuanysh","family":"Seitkamal","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, Nazarbayev University","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arailym","family":"Bertleuova","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, Nazarbayev University","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Bulanin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, School of Medicine, Nazarbayev University","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai A.","family":"Barlev","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Oncology, National Laboratory Astana","place":["Astana, Kazakhstan"]},{"name":"Department of Biomedical Sciences, School of Medicine, Nazarbayev University","place":["Astana, Kazakhstan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41419-025-07454-x","article-title":"CAR-T therapy dilemma and innovative design strategies for next generation","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Mol Ther Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imm.70094","article-title":"Barriers and strategies to enhance CAR-T cell infiltration in solid tumours: A systematic review","volume":"178","author":"Zhang","year":"2026","journal-title":"Immunology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340702","article-title":"Crosstalk between T lymphocyte and extracellular matrix in tumor microenvironment","volume":"15","author":"Lv","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s43556-026-00415-6","article-title":"The extracellular matrix in inflammation and cancer","volume":"7","author":"Zhang","year":"2026","journal-title":"Mol BioMed"},{"key":"B7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic barriers to T cell function in tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.02.008","article-title":"Lactate: A key regulator of the immune response","volume":"58","author":"Llibre","year":"2025","journal-title":"Immunity"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq3016","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8","author":"Peng","year":"2023","journal-title":"Sci Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14466","article-title":"A guide to chemokines and their receptors","volume":"285","author":"Hughes","year":"2018","journal-title":"FEBS J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.18.1.217","article-title":"The biology of chemokines and their receptors","volume":"18","author":"Rossi","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biophys-051013-022942","article-title":"What do structures tell us about chemokine receptor function and antagonism","volume":"46","author":"Kufareva","year":"2017","journal-title":"Annu Rev Biophys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01345.x","article-title":"Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases","volume":"105","author":"Curnock","year":"2002","journal-title":"Immunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41392-024-01803-6","article-title":"G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100543","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00262-025-04278-8","article-title":"Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy","volume":"75","author":"Zhang","year":"2026","journal-title":"Cancer Immunol Immunother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.21.16.5299-5305.2001","article-title":"NF-kappaB signals induce the expression of c-FLIP","volume":"21","author":"Micheau","year":"2001","journal-title":"Mol Cell Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.20.8.2687-2695.2000","article-title":"The Rel\/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L)","volume":"20","author":"Chen","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2026.06.007","article-title":"PANoptosis in life and death across cell types: From innate immunity to therapeutic implications","volume":"33","author":"Zengeler","year":"2026","journal-title":"Cell Chem Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00765-9","article-title":"PANoptosis: bridging apoptosis, pyroptosis, and necroptosis in cancer progression and treatment","volume":"31","author":"Gao","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1893466","article-title":"Tumor-intrinsic determinants of immunogenic cell death modalities","volume":"10","author":"Workenhe","year":"2021","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7554\/elife.56554","article-title":"Cytotoxic T cells swarm by homotypic chemokine signalling","volume":"9","author":"Galeano Ni\u00f1o","year":"2020","journal-title":"Elife"},{"key":"B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.cir-18-0277","article-title":"T cell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1593\/neo.121572","article-title":"CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network","volume":"15","author":"Boissonnas","year":"2013","journal-title":"Neoplasia"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2026.03.017","article-title":"Targeting cytokine\/chemokine signaling to convert immunologically cold tumors into hot: emerging strategies in cancer immunotherapy","volume":"16","author":"Park","year":"2026","journal-title":"Acta Pharm Sin B"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.3.963","article-title":"Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes","volume":"184","author":"Loetscher","year":"1996","journal-title":"J Exp Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/19768354.2024.2402024","article-title":"CXCL10 promotes melanoma angiogenesis and tumor growth","volume":"28","author":"Kim","year":"2024","journal-title":"Anim Cells Syst (Seoul)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6362","article-title":"The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10","volume":"172","author":"Abel","year":"2004","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00737-6","article-title":"T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours","volume":"5","author":"Lesch","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1331287","article-title":"The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context","volume":"14","author":"Chia","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2026.117415","article-title":"Natural killer cells swarm and cross-recruit cytotoxic T cells via CCR5","volume":"45","author":"Cremasco","year":"2026","journal-title":"Cell Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1988-9","article-title":"CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma","volume":"66","author":"Umansky","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18081271","article-title":"CCL5 orchestrates paradoxical immune landscapes in NSCLC: simultaneous recruitment of effector and suppressor cells shapes immunotherapy resistance","volume":"18","author":"Li","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","article-title":"CCL2\/CCR2 signaling in cancer pathogenesis","volume":"18","author":"Hao","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3604","article-title":"Retinoblastoma inactivation induces a protumoral microenvironment via enhanced CCL2 secretion","volume":"79","author":"Li","year":"2019","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/s41467-019-13204-3","article-title":"Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy","volume":"10","author":"Shi","year":"2019","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00974-6","article-title":"The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention","volume":"20","author":"Cambier","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ccell.2023.03.004","article-title":"Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.molcel.2025.01.024","article-title":"Molecular basis of promiscuous chemokine binding and structural mimicry at the C-X-C chemokine receptor, CXCR2","volume":"85","author":"Saha","year":"2025","journal-title":"Mol Cell"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00263","article-title":"CXCR2: From bench to bedside","volume":"3","author":"Stadtmann","year":"2012","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170277","article-title":"CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes","volume":"216","author":"Rapp","year":"2019","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1815515116","article-title":"Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.1MR0520-746R","article-title":"Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors","volume":"108","author":"Donnadieu","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01443-y","article-title":"T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control","volume":"24","author":"Steele","year":"2023","journal-title":"Nat Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.10.005","article-title":"Life and death decision-making by p53 and implications for cancer immunotherapy","volume":"7","author":"Liu","year":"2021","journal-title":"Trends Cancer"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.4161\/cc.5.12.2820","article-title":"Lysine methylation goes global","volume":"5","author":"Morgunkova","year":"2006","journal-title":"Cell Cycle"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.73","article-title":"The microRNA and p53 families join forces against cancer","volume":"17","author":"Barlev","year":"2010","journal-title":"Cell Death Differ"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.009","article-title":"Understanding the complexity of p53 in a new era of tumor suppression","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.258","article-title":"Human EHMT2\/G9a activates p53 through methylation-independent mechanism","volume":"36","author":"Rada","year":"2017","journal-title":"Oncogene"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41392-025-02549-5","article-title":"p53: from understanding its structure to advances in therapeutic targeting","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.928399","article-title":"Opposing roles of wild-type and mutant p53 in the process of epithelial to mesenchymal transition","volume":"9","author":"Semenov","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051116","article-title":"Inhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of I\u03baB","volume":"7","author":"Son","year":"2012","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e29","article-title":"Chemokine network and overall survival in TP53 wild-type and mutant ovarian cancer","volume":"18","author":"Ignacio","year":"2018","journal-title":"Immune Netw"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/nature08462","article-title":"Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma","volume":"462","author":"Meylan","year":"2009","journal-title":"Nature"},{"key":"B80","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-026-02659-w","article-title":"KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers","volume":"25","author":"Yan","year":"2026","journal-title":"Mol Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","article-title":"KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer","volume":"35","author":"Liao","year":"2019","journal-title":"Cancer Cell"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209237","article-title":"K-ras activation generates an inflammatory response in lung tumors","volume":"25","author":"Ji","year":"2006","journal-title":"Oncogene"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc cooperates with Ras by programming inflammation and immune suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B85","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2024.156504","article-title":"Atypical chemokine receptors in cancer","volume":"176","author":"Samus","year":"2024","journal-title":"Cytokine"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.009","article-title":"Atypical chemokine receptors: emerging therapeutic targets in cancer","volume":"43","author":"Torphy","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and chemokine receptors: new targets for cancer immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304190120","article-title":"The spread of interferon-\u03b3 in melanomas is highly spatially confined, driving nongenetic variability in tumor cells","volume":"120","author":"Centofanti","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.7150\/thno.68966","article-title":"A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level","volume":"12","author":"Pfeifer","year":"2022","journal-title":"Theranostics"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.1500","article-title":"Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells","volume":"264","author":"Naujokat","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603918","article-title":"Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation","volume":"97","author":"Minas","year":"2007","journal-title":"Br J Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2269-y","article-title":"Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism","volume":"68","author":"Zhu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-025-01009-x","article-title":"CAR-engineered lymphocyte persistence is governed by a FAS ligand-FAS autoregulatory circuit","volume":"6","author":"Yi","year":"2025","journal-title":"Nat Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181482","article-title":"Targeting the CXCR4\/CXCL12 axis to overcome drug resistance in triple-negative breast cancer","volume":"14","author":"Singh","year":"2025","journal-title":"Cells"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1387198","article-title":"Signaling crosstalk between tumor endothelial cells and immune cells in the microenvironment of solid tumors","volume":"12","author":"Xu","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00766","article-title":"Tumor endothelial cells (TECs) as potential immune directors of the tumor microenvironment - new findings and future perspectives","volume":"8","author":"Nagl","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.667.bloodjournal882667","article-title":"Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium","volume":"88","author":"Griffioen","year":"1996","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584723","article-title":"A window of opportunity: targeting cancer endothelium to enhance immunotherapy","volume":"11","author":"Duru","year":"2020","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367875","article-title":"Endothelial cells in tumor microenvironment: insights and perspectives","volume":"15","author":"Leone","year":"2024","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B107","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba6110","article-title":"Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer","volume":"13","author":"Oresta","year":"2021","journal-title":"Sci Transl Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1667\/RR1860.1","article-title":"Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation","volume":"173","author":"Matsumura","year":"2010","journal-title":"Radiat Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111739","article-title":"HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4","volume":"209","author":"Schiraldi","year":"2012","journal-title":"J Exp Med"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00570-7","article-title":"Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-\u03b3 is a major determinant of CD4+ CAR T-cell antitumor activity","volume":"4","author":"Boulch","year":"2023","journal-title":"Nat Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0428","article-title":"Antagonism of IAPs enhances CAR T-cell efficacy","volume":"7","author":"Michie","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0837","article-title":"CAR T-cell entry into tumor islets is a two-step process dependent on IFN\u03b3 and ICAM-1","volume":"9","author":"Kantari-Mimoun","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41419-026-08993-7","article-title":"Necroptotic cell death and immunomodulator release induced by T-cell engaging anti-lymphoma therapies","volume":"17","author":"Both","year":"2026","journal-title":"Cell Death Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax7969","article-title":"Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome","volume":"5","author":"Liu","year":"2020","journal-title":"Sci Immunol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020100","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41591-018-0057-z","article-title":"A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade","volume":"24","author":"Thommen","year":"2018","journal-title":"Nat Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.coi.2019.04.014","article-title":"Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections","volume":"58","author":"Philip","year":"2019","journal-title":"Curr Opin Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-025-02371-z","article-title":"Immunosenescence: signaling pathways, diseases and therapeutic targets","volume":"10","author":"Fu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0894","article-title":"T-cell senescence in the tumor microenvironment","volume":"13","author":"Huang","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","article-title":"CAR-T cells in solid tumors: challenges and breakthroughs","volume":"6","author":"Escobar","year":"2025","journal-title":"Cell Rep Med"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010709","article-title":"Prior chemotherapy deteriorates T-cell quality for CAR T-cell therapy in B-cell non-Hodgkin's lymphoma","volume":"13","author":"Herzberg","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02234-x","article-title":"The long-term effects of chemotherapy on normal blood cells","volume":"57","author":"Mitchell","year":"2025","journal-title":"Nat Genet"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nature22367","article-title":"Chromatin states define tumour-specific T cell dysfunction and reprogramming","volume":"545","author":"Philip","year":"2017","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nri3740","article-title":"T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion","volume":"14","author":"Speiser","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0760-z","article-title":"Early precursor T cells establish and propagate T cell exhaustion in chronic infection","volume":"21","author":"Utzschneider","year":"2020","journal-title":"Nat Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41467-017-02689-5","article-title":"Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41590-020-00829-6","article-title":"NF-\u03baB-inducing kinase maintains T cell metabolic fitness in antitumor immunity","volume":"22","author":"Gu","year":"2021","journal-title":"Nat Immunol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B134","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s43018-022-00490-y","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.04.004","article-title":"Decoding and overcoming T cell exhaustion: epigenetic and transcriptional dynamics in CAR-T cells against solid tumors","volume":"32","author":"Ahn","year":"2024","journal-title":"Mol Ther"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1866287","article-title":"Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures","volume":"10","author":"Wang","year":"2021","journal-title":"Oncoimmunology"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0178","article-title":"Single-cell RNA analysis reveals cell-intrinsic functions of CAR T cells correlating with response in a phase II study of lymphoma patients","volume":"29","author":"Sar\u00e9n","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820","article-title":"Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL","volume":"8","author":"Bai","year":"2022","journal-title":"Sci Adv"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07762-w","article-title":"Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission","volume":"634","author":"Bai","year":"2024","journal-title":"Nature"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B141","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202521975","article-title":"Enhancing CAR-T cell efficacy in solid tumors by inhibiting CCL5\/VEGF-mediated angiogenesis","volume":"13","author":"Sun","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.43653","article-title":"CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors","volume":"8","author":"Walens","year":"2019","journal-title":"Elife"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2913","article-title":"Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity","volume":"77","author":"Ban","year":"2017","journal-title":"Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501791122","article-title":"Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy","volume":"122","author":"Lugassy","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzz043","article-title":"Designing an improved T-cell mobilising CXCL10 mutant through enhanced GAG binding affinity","volume":"32","author":"Gerlza","year":"2019","journal-title":"Protein Eng Des Sel"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02853-3","article-title":"Enhanced anti-tumor efficacy of IL-7\/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models","volume":"70","author":"Goto","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0777","article-title":"Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion","volume":"26","author":"Luo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/advs.75993","article-title":"CCL3 and IL-7 synergistically enhance CAR-T efficacy in solid tumors","volume":"13","author":"Chen","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121675","article-title":"At the crossroads of the cGAS-cGAMP-STING pathway and the DNA damage response: Implications for cancer progression and treatment","volume":"16","author":"Korneenko","year":"2023","journal-title":"Pharm (Basel)"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013692","article-title":"Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling","volume":"14","author":"Roulstone","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1839684","article-title":"A CDK4\/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer","volume":"17","author":"Zhou","year":"2026","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2026.116980","article-title":"CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth","volume":"185","author":"Zhao","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.omto.2019.12.003","article-title":"Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9","volume":"16","author":"Eckert","year":"2020","journal-title":"Mol Ther Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395997","article-title":"Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines","volume":"7","author":"Moon","year":"2018","journal-title":"Oncoimmunology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0324","article-title":"Combination CXCR4 and PD-1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma","volume":"13","author":"Morita","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-023-00625-0","article-title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma","volume":"10","author":"Lei","year":"2024","journal-title":"Cell Discov"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1182\/blood-2024-200932","article-title":"CD30.CAR-T cells co-expressing the CCR4 chemokine receptor in relapsed\/refractory Hodgkin lymphoma","volume":"144","author":"Grover","year":"2024","journal-title":"Blood"},{"key":"B163","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1182\/blood-2024-201799","article-title":"Phase 1 trial of CD30-directed, CCR4 co-expressing chimeric antigen receptor T-cells in patients with CD30+ cutaneous T-cell lymphomas refractory to brentuximab vedotin","volume":"144","author":"Reef","year":"2024","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","article-title":"Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01684-0","article-title":"Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia","volume":"41","author":"Gottschlich","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.110332","article-title":"The role of single cell transcriptomics for efficacy and toxicity profiling of chimeric antigen receptor (CAR) T cell therapies","volume":"192","author":"Thomas","year":"2025","journal-title":"Comput Biol Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011308","article-title":"Single-cell spatial transcriptomics unravels cell states and ecosystems associated with clinical response to immunotherapy","volume":"13","author":"Abdulrahman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-026-03152-x","article-title":"Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumors","author":"Lu","year":"2026","journal-title":"Nat Biotechnol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116827","article-title":"In situ multi-modal characterization of pancreatic cancer reveals tumor cell identity as a defining factor of the surrounding microenvironment","volume":"45","author":"Lyubetskaya","year":"2026","journal-title":"Cell Rep"},{"key":"B171","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41467-019-13880-1","article-title":"Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy","volume":"11","author":"Sheih","year":"2020","journal-title":"Nat Commun"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13073-025-01498-6","article-title":"The CXCL16\/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"17","author":"Lu","year":"2025","journal-title":"Genome Med"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01959-0","article-title":"Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma","volume":"28","author":"Haradhvala","year":"2022","journal-title":"Nat Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101803","article-title":"Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias","volume":"5","author":"Guerrero-Murillo","year":"2024","journal-title":"Cell Rep Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113263","article-title":"Functional diversification and dynamics of CAR-T cells in patients with B-ALL","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024381","article-title":"Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma","volume":"144","author":"Maurer","year":"2024","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100227","article-title":"Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors","volume":"2","author":"Kosti","year":"2021","journal-title":"Cell Rep Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01124-3","article-title":"Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial","volume":"7","author":"Gao","year":"2026","journal-title":"Nat Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1378944","article-title":"Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives","volume":"15","author":"Levstek","year":"2024","journal-title":"Front Immunol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1963794\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:12:11Z","timestamp":1791367931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1963794\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":182,"alternative-id":["10.3389\/fimmu.2026.1963794"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1963794","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1963794"}}